Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M

ARDELYX, INC.

2025-Q1 EPS reported -$0.17 revenue$74,114,000

Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.
IBSRELA net product sales $44.4M (+57% YoY); FY2025 guidance reaffirmed at $240–250M.
XPHOZAH net product sales $23.4M (+30% ex-returns reserve); $5.0M milestone from Fosun for China tenapanor approval.
Cash $214.0M (Dec 2024: $250.1M); SG&A $83.2M, R&D $14.9M.
Appointed Merdad Parsey to Board and Laura Williams as Chief Patient Officer in April 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.